Hot Stocks

Hot stocks are not about hype. They emerge when powerful themes, policy shifts, and capital flows converge. InvestorPlace analysts track fast-moving market narratives, especially in technology, AI, and infrastructure, to identify stocks drawing outsized attention and explain what is really driving those moves.

Where Will You Put Your Money in 2012?

By Louis Navellier, Editor, Growth Investor
Two areas of the market are slated to do well in the upcoming months and year, but be wary of this one sector.

Is Sears the Next Berkshire Hathaway?

By Charles Sizemore, Chief Investment Strategist, The Freeport Society
Don't laugh. Eddie Lampert's strategy at Sears Holdings could be regarded as being very similar to Warren Buffett's makeover of Berkshire Hathaway in the sixties.

Sears Slammed After Store Closings — Tuesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Sears shares plummet 27% after announcing the company would close 100 to 120 Sears and Kmart locations.

5 Biggest Market Blunders of 2011

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
This year was overflowing with examples of bad management, bad decision making and bogus data. Here are the top five worst cases.

Sears Shedding Stores as it Sinks

By Jeff Reeves
Sure, a bad economy has forced Sears' hand in the closure of a hundred stores -- but years of declining sales and other factors weigh on the retailer's future.

InvestorPlace.com Editor’s Best (and Worst) Calls of 2011

By Jeff Reeves
Take a look back at InvestorPlace.com editor Jeff Reeve's 2011 stock pick gems like AmBev -- and duds like BofA.

3 Top Takeover Candidates for 2012

By Tom Taulli, InvestorPlace Contributor
With acquirers hungry and loaded with cash, it could be a busy year for M&A. And these three companies could lead the list of likely buyout candidates.

AOL Investors Ask: How Much Longer?

By Jonathan Berr, InvestorPlace Contributor
After two years, CEO Tim Armstrong's turnaround is still not done. And now a big shareholder is getting antsy.

Netflix’s Reed Hastings Still Doesn’t Get It

By Tom Taulli, InvestorPlace Contributor
Cutting his stock option award in half -- which still leaves it at $1.5 million -- is scant help for burned investors.

Gold, Silver Prices Mixed On Hopeful Economic Data

By Andrew Burger, InvestorPlace Contributor
Stronger economic numbers lift silver while holding gold close to the flat line.

Intel Chipped By Shrinking Demand

By Jon Markman, Editor, Trader's Advantage and CounterPoint Options
Thai flooding this summer certainly made a dent in Intel's business this year, but there have been several indications that PC sales were slowing before that.

Yahoo’s Parts Are Worth More Than Its Sum

By Tom Taulli, InvestorPlace Contributor
As the company mulls the sale of its Asian assets, its core operations are likely undervalued.

Precious Metals, Miners Lower as Jobless Claims Hit 44-Month Low

By Andrew Burger, InvestorPlace Contributor
Gold and silver were off just less than 1% in Thursday morning trading, and mining shares were broadly lower as well.

Toyota in the Comeback Driver’s Seat for 2012

By Jeff Reeves
Toyota is projected to drop from No. 1 to No. 3 in global sales this year, but ambitious plans could propel TM back to the top spot.

The Case Against Arthur Sulzberger at The New York Times

By Jonathan Berr, InvestorPlace Contributor
His record as chairman since 1997 has been terrible for shareholders. NYT needs new blood as a leader , someone like Ford's Alan Mulally.

Walgreen Not Sweating Loss of Express Scripts Customers to CVS — Should It Be?

By Barry Cohen, Health Care Writer
CVS says it could gobble up to 23M prescriptions that Walgreens has sold through Express Scripts if a deal isn't announced. So far, WAG is sticking to its guns.

Blame Bargains for Best Buy’s Demise

By Jon Markman, Editor, Trader's Advantage and CounterPoint Options
Best Buy's problem isn't unique among retailers -- businesses need sales to bring in price-conscious consumers, but their revenues are getting killed.

Oracle Decks Techs — Wednesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
The software giant's first earnings miss in a decade didn't go over well.

Ariad Pharmaceuticals Still Might Have Upside

By Barry Cohen, Health Care Writer
Ariad Pharmaceuticals is up 120% in the past 12 months, mostly fueled on optimism over its trial leukemia treatment. But some analysts think the ceiling is higher.
Load More Articles